Clinical Behavior and Molecular Insights of Secretory Carcinoma of Salivary Glands, a Single Center Experience

Objective: the study aimed to characterize the novel entity referred to as secretory carcinoma of the salivary glands. Methods: we comprehensively evaluated 150 patients afflicted by malignant salivary gland tumors who had been under treatment at the University of Verona. Inclusion criteria primaril...

Full description

Saved in:
Bibliographic Details
Published in:Indian journal of otolaryngology, and head, and neck surgery and head, and neck surgery, 2024-10, Vol.76 (5), p.4153-4162
Main Authors: Bassani, Sara, Fiorini, Denise, Destefanis, Miriam Sara, Arsie, Athena Eliana, Mulone, Davide, Eccher, Albino, Brunelli, Matteo, Marani, Filippo, Monzani, Daniele, Molteni, Gabriele
Format: Article
Language:English
Subjects:
Cancer
Exocrine glands
Head & neck cancer
Head and Neck Surgery
Medicine
Medicine & Public Health
Mutation
Oral cancer
Original
Original Article
Otorhinolaryngology
Pathology
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective: the study aimed to characterize the novel entity referred to as secretory carcinoma of the salivary glands. Methods: we comprehensively evaluated 150 patients afflicted by malignant salivary gland tumors who had been under treatment at the University of Verona. Inclusion criteria primarily focused on the availability of paraffin block materials and adequate follow-up data. Subsequently, we conducted a comprehensive Fluorescent In Situ Hybridization (FISH) analysis, utilizing probes targeting NTRK-3, MALM-2, EWRS-1, HER-2, MDM-2, and NTRK1-2. Results: out of the initial cohort, 37 patients met the eligibility criteria for our study. We identified NTRK3 gene rearrangements in four patients (11%), two of whom had mucoepidermoid carcinoma, and the remaining two had acinic cell carcinoma. Notably, none of these patients had initially received a secretory carcinoma diagnosis. The primary treatment approach for all patients entailed surgical parotid gland resection. The overall survival (OS) for patients with NTRK3 rearrangements amounted to 78 months, with a corresponding progression-free survival (PFS) of 73 months. Conclusion: in summary, our case series suggests that secretory carcinomas exhibit a favorable clinical course and underscores the pivotal importance of distinguishing secretory carcinomas from other histological subtypes.
ISSN:2231-3796
0973-7707
DOI:10.1007/s12070-024-04807-4